Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. While pregnant with her third child ...

Add Yahoo as a preferred source to see more of our stories on Google. The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness ...

WASHINGTON -- The U.S. Food and Drug Administration has approved the first maternal vaccine intended to help protect newborns against respiratory syncytial virus (RSV). The vaccine would be given ...

CXCL12 and CXCL13 are potential biomarkers for RSV bronchiolitis severity and recurrence risk, with elevated levels indicating severe cases and recurrent wheezing, respectively. RSV remains a major ...

New data reveals that Montana is among the top states in the nation for protecting infants from Respiratory Syncytial Virus ...

NEW YORK CITY -- In September, an 8-month-old baby came into Dr. Juanita Mora's office in Chicago with an infection the doctor hadn't expected to see for another two months: RSV. Like her peers across ...

Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and children, it causes only mild, cold-like symptoms and goes away on its own.

New Jersey health data shows RSV activity continuing statewide, with hospitalizations concentrated among young children and older adults.

Respiratory infections are the leading causes of hospitalizations, ED visits and mortality in children in the United States ...

The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness at bay with yearly shots. While flu and COVID-19 vaccines are an ...